



Human VEGF ELISA

Catalog Number EA-0401

(For Research Use Only)

Introduction

Vascular endothelial growth factor (VEGF) is one of the most potent and specific tumor-angiogenic factors (1, 2). VEGF is used by oxygen-hungry cells to promote growth of blood vessels. It binds to specialized receptors on the surfaces of endothelial cells and induces to build new vessels. Most tumors produce VEGF and inhibition of VEGF-induced angiogenesis significantly inhibits tumor growth in vivo (3-5). A number of antiangiogenic drugs have shown to be capable of decreasing the number of vessels. VEGF expression correlates with microvessel density in a number of solid malignancies including carcinomas of the breast, lung, prostate, and colon (6-9).

Principle of the assay

VEGF ELISA is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay utilizes a mouse anti-human VEGF antibody for immobilization on the microtiter wells and goat anti-human VEGF antibodies along with streptavidin conjugated to horseradish peroxidase (HRP) for detection. The test sample is allowed to react simultaneously with the two antibodies, resulting in the VEGF molecules being sandwiched between the solid phase and enzyme-linked antibodies. After incubation, the wells are washed to remove unbound-labeled antibodies. A HRP substrate, TMB, is added to result in the development of a blue color. The color development is then stopped with the addition of Stop Solution changing the color to yellow. The concentration of VEGF is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450 nm.




Diagram of ELISA

Materials provided with the kit

- 96 well microplate coated with anti-human VEGF antibodies (4°C).
- Biotin labeled anti-human VEGF antibodies (-20°C).
- Streptavidin-HRP conjugate (4°C).
- Recombinant VEGF standard (1µg/ml) (-20°C).
- 1X Diluent buffer (4°C).
- 5X Assay wash buffer (RT)
- Substrate (4°C).
- Stop Solution (4°C).

Material required but not provided

- Microplate reader capable of measuring absorbance at 450 nm
- Deionized or distilled water.

Reagent preparation before starting experiment

- Dilute the 5x Assay wash buffer to 1x buffer
40ml 5x Assay wash buffer
160ml ddH₂O
- Dilute 500 times of human recombinant VEGF (1µg/ml) with 1X Diluent buffer to 2ng/ml and then 2-fold serial dilutions.
- Dilute 400 times of biotin labeled anti-human VEGF antibodies with 1X Diluent buffer before use.
- Dilute 200 times of streptavidin-HRP with 1X Diluent buffer before use.

Assay procedure

1. Cut the sealing film over the plate and remove it from the desired number of well strips. Make sure the rest of wells are well sealed.
2. Add 100 µl of Standard, control, or sample per well and incubate for 1 hour at room temperature with gentle shaking.
3. Aspirate each well and wash by adding 200µl of 1X Assay wash buffer. Repeat the process three times for a total of three washes. Complete removal of liquid at each wash. After the last wash, remove any remaining liquid by inverting the plate against clean paper towels.
4. Add 100µl of diluted biotin-labeled anti-human VEGF antibodies to each well and incubate for 1 hour at room temperature with gentle shaking.
5. Repeat the aspiration/wash as in step 3.
6. Add 100 µl of diluted streptavidin-HRP conjugate to each well and incubate for 45 min at room temperature with gentle shaking.
7. Repeat the aspiration/wash as in step 3.
8. Add 100µl substrate to each well and incubate for 5-30 minutes.
9. Add 50µl of Stop solution to each well. The color in the wells should change from blue to yellow.
10. Determine the optical density of each well with a microplate reader at 450 nm within 30 minutes.

References

- (1) Zhang HT, Craft P, Scott PA et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. *J Natl Cancer Inst* 1995;87:213-219.
- (2) Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. *Cancer Metastasis Rev* 1996;15:165-176.
- (3) Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. *Nature* 1993;362:841-844.
- (4) Millauer B, Shawver LK, Plate KH et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. *Nature* 1994;367:576-579.
- (5) Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. *Cancer Res* 1996;56:393-401
- (6) Linderholm B, Tavelin B, Grankvist K et al. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. *J Clin Oncol* 1998;16:3121-3128.
- (7) Takahashi Y, Kitadai Y, Bucana CD et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. *Cancer Res* 1995;55:3964-3968.
- (8) Weidner N, Carroll PR, Flax J et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. *Am J Pathol* 1993;143:401-409.
- (9) Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. *Br J Cancer* 1996;73:931-934.

Example of standard curve

